BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 37524847)

  • 1. A comprehensive genomic study of 390 H3F3A-mutant pediatric and adult diffuse high-grade gliomas, CNS WHO grade 4.
    Williams EA; Brastianos PK; Wakimoto H; Zolal A; Filbin MG; Cahill DP; Santagata S; Juratli TA
    Acta Neuropathol; 2023 Sep; 146(3):515-525. PubMed ID: 37524847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinicopathological characteristics and prognosis of diffuse midline gliomas with histone H3K27M mutation: an analysis of 30 cases].
    Li HN; Shan CG; Fan CZ; Cheng LN; Wu SG; Liu MT; Jiang GY; Li Z
    Zhonghua Bing Li Xue Za Zhi; 2019 Mar; 48(3):192-198. PubMed ID: 30831644
    [No Abstract]   [Full Text] [Related]  

  • 3. Transcriptomic and epigenetic profiling of 'diffuse midline gliomas, H3 K27M-mutant' discriminate two subgroups based on the type of histone H3 mutated and not supratentorial or infratentorial location.
    Castel D; Philippe C; Kergrohen T; Sill M; Merlevede J; Barret E; Puget S; Sainte-Rose C; Kramm CM; Jones C; Varlet P; Pfister SM; Grill J; Jones DTW; Debily MA
    Acta Neuropathol Commun; 2018 Nov; 6(1):117. PubMed ID: 30396367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adult diffuse midline gliomas: Clinical, radiological, and genetic characteristics.
    Dono A; Takayasu T; Ballester LY; Esquenazi Y
    J Clin Neurosci; 2020 Dec; 82(Pt A):1-8. PubMed ID: 33317715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of prognostic markers in diffuse midline gliomas H3K27M-mutant.
    Dufour C; Perbet R; Leblond P; Vasseur R; Stechly L; Pierache A; Reyns N; Touzet G; Le Rhun E; Vinchon M; Maurage CA; Escande F; Renaud F
    Brain Pathol; 2020 Jan; 30(1):179-190. PubMed ID: 31348837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advanced MR imaging and
    Piccardo A; Tortora D; Mascelli S; Severino M; Piatelli G; Consales A; Pescetto M; Biassoni V; Schiavello E; Massollo M; Verrico A; Milanaccio C; Garrè ML; Rossi A; Morana G
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(8):1685-1694. PubMed ID: 31030232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diffuse hemispheric glioma with H3 p.K28M (K27M) mutation: Unusual non-midline presentation of diffuse midline glioma, H3 K27M-altered?
    Donev K; Sundararajan V; Johnson D; Balan J; Chambers M; Paulson VA; Scherpelz KP; Abdullaev Z; Quezado M; Cimino PJ; Pratt D; Valerio E; Alves de Castro JV; Carraro DM; Torrezan GT; Wolff BM; Kulikowski LD; Costa FD; Aldape K; Ida CM
    J Neuropathol Exp Neurol; 2024 Apr; 83(5):357-364. PubMed ID: 38447592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics of diffuse hemispheric gliomas, H3 G34-mutant in adults.
    Picart T; Barritault M; Poncet D; Berner LP; Izquierdo C; Tabouret E; Figarella-Branger D; Idbaïh A; Bielle F; Bourg V; Vandenbos FB; Moyal EC; Uro-Coste E; Guyotat J; Honnorat J; Gabut M; Meyronet D; Ducray F
    Neurooncol Adv; 2021; 3(1):vdab061. PubMed ID: 34056608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High frequency of PDGFRA and MUC family gene mutations in diffuse hemispheric glioma, H3 G34-mutant: a glimmer of hope?
    Hu W; Duan H; Zhong S; Zeng J; Mou Y
    J Transl Med; 2022 Feb; 20(1):64. PubMed ID: 35109850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new subtype of diffuse midline glioma, H3 K27 and BRAF/FGFR1 co-altered: a clinico-radiological and histomolecular characterisation.
    Auffret L; Ajlil Y; Tauziède-Espariat A; Kergrohen T; Puiseux C; Riffaud L; Blouin P; Bertozzi AI; Leblond P; Blomgren K; Froelich S; Picca A; Touat M; Sanson M; Beccaria K; Blauwblomme T; Dangouloff-Ros V; Boddaert N; Varlet P; Debily MA; Grill J; Castel D
    Acta Neuropathol; 2023 Dec; 147(1):2. PubMed ID: 38066305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Significance of H3K27M mutation with specific histomorphological features and associated molecular alterations in pediatric high-grade glial tumors.
    Bozkurt SU; Dagcinar A; Tanrikulu B; Comunoglu N; Meydan BC; Ozek M; Oz B
    Childs Nerv Syst; 2018 Jan; 34(1):107-116. PubMed ID: 29063957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicohistoradiological and surgical outcome in diffuse midline glioma.
    Kumar Suman A; Bhattacharjee S; Uppin MS; Fathima ST
    Childs Nerv Syst; 2024 Jan; 40(1):65-71. PubMed ID: 37644138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncohistones and disrupted development in pediatric-type diffuse high-grade glioma.
    Ocasio JK; Budd KM; Roach JT; Andrews JM; Baker SJ
    Cancer Metastasis Rev; 2023 Jun; 42(2):367-388. PubMed ID: 37119408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Indicators for H3K27M-Mutant Diffuse Midline Glioma: A Population-Based Retrospective Surveillance, Epidemiology, and End Results Database Analysis.
    Adhikari S; Bhutada AS; Ladner L; Cuoco JA; Entwistle JJ; Marvin EA; Rogers CM
    World Neurosurg; 2023 Oct; 178():e113-e121. PubMed ID: 37423332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Morphological diversity in H3G34-mutant high-grade gliomas: Ganglionic and epithelioid features.
    Gilani A; Kleinschmidt-DeMasters BK
    Clin Neuropathol; 2021; 40(1):4-10. PubMed ID: 32631482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted therapy with anlotinib for a H3K27M mutation diffuse midline glioma patient with PDGFR-α mutation: a case report.
    Wang Q; Niu W; Pan H
    Acta Neurochir (Wien); 2022 Aug; 164(8):2063-2066. PubMed ID: 34812950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. STAT3 is a biologically relevant therapeutic target in H3K27M-mutant diffuse midline glioma.
    Zhang L; Nesvick CL; Day CA; Choi J; Lu VM; Peterson T; Power EA; Anderson JB; Hamdan FH; Decker PA; Simons R; Welby JP; Siada R; Ge J; Kaptzan T; Johnsen SA; Hinchcliffe EH; Daniels DJ
    Neuro Oncol; 2022 Oct; 24(10):1700-1711. PubMed ID: 35397475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differences in survival prognosticators between children and adults with H3K27M-mutant diffuse midline glioma.
    Gong X; Kuang S; Deng D; Wu J; Zhang L; Liu C
    CNS Neurosci Ther; 2023 Dec; 29(12):3863-3875. PubMed ID: 37311690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Case series of diffuse extraneural metastasis in H3F3A mutant high-grade gliomas: Clinical, molecular phenotype and literature review.
    Mohiuddin S; Maraka S; Usman Baig M; Gupta S; Muzzafar T; Valyi-Nagy T; Lindsay H; Moody K; Razvi S; Paulino A; Slavin K; Gondi V; McCutcheon I; Zaky W; Khatua S
    J Clin Neurosci; 2021 Jul; 89():405-411. PubMed ID: 34053821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significance of H3K27M Mutation in "Nonmidline" High-Grade Gliomas of Cerebral Hemispheres.
    La Rocca G; Sabatino G; Altieri R; Signorelli F; Ricciardi L; Gessi M; Della Pepa GM
    World Neurosurg; 2019 Nov; 131():174-176. PubMed ID: 31415896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.